SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 23, 2003
Sirna Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | | 0-27914 | | 34-1697351 |
(State or other jurisdiction of incorporation) | | (Commission File No.) | | (I.R.S. Employer Identification Number |
2950 Wilderness Place Boulder, Colorado 80301
(Address of principal executive offices)
Registrant’s telephone number, including area code: (303) 449-6500
N/A
(Former name or former address, if changed since last report.)
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE
Effective December 31, 2003, Marvin Tancer, Vice President, Operations and Chief Financial Officer, will depart from Sirna Therapeutics to pursue other opportunities.
A copy of the press release issued by the Company on December 23, 2003 is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(c) Exhibits
| 99.1 | Press Release issued by the Company on December 23, 2003. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Sirna Therapeutics, Inc.
(Registrant)
By: /s/ Howard W. Robin
Name: Howard W. Robin
Title: President & Chief Executive Officer
3
EXHIBIT INDEX
Exhibit No. | | Description of Exhibit |
| |
99.1 | | Press Release issued by the Company on December 23, 2003. |
4
